Literature DB >> 11420

Dexclamol: effects on catecholamine metabolism and demonstration of stereochemical specificity of antagonism of central adrenergic receptors.

T A Pugsley, W Lippmann.   

Abstract

The effects of the benzocycloheptapyridoisoquinolinol derivative (+)-dexclamol-HCl and some of those of (+/-)-dexclamol and the corresponding (-)-dexclamol were compared to those of the potent neuroleptic agents droperidol and fluphenazine on norepinephrine (NE) and dopamine (DA) turnover in the whole brain and in the striatum of rats. Differences in NE and DA depletion following tyrosine hydroxylase inhibition with alpha-methyl-p-tyrosine indicated that (+)-dexclamol and droperidol increased DA turnover with no effect on NE turnover. At a higher dose both (+)-dexclamol and droperidol, but not (-)-dexclamol, accelerated DA turnover and also that of NE. A decrease in DA concentration occurred after both drugs under the latter condition only. (+)-Dexclamol, (+/-)-dexclamol and droperidol exhibited a similar onset of action employing striatal homovanillic acid (HVA) increase as indicative of DA turnover changes. The duration of action of droperidol was shorter than for (+)-dexclamol and (+/-)-dexclamol; fluphenazine displayed a slower onset and longer duration of activity. The (-)-dexclamol was ineffective. (+)-Dexclamol, droperidol and phentolamine reduced the concentrations of 3H-NE in heart when given after the 3H-NE, a probable indication of increased NE release due to adrenergic receptor blockade. The present findings demonstrate that the neuroleptic agent (+)-dexclamol, but not (-)-dexclamol, affects central DA and NE turnover and indicates a stereochemical specificity with respect to antagonism of central DA and NE receptors.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 11420     DOI: 10.1007/BF00499442

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  42 in total

1.  The pharmacology of dehydrobenzperidol, a new potent and short acting neuroleptic agent chemically related to Haloperidol.

Authors:  P A JANSSEN; C J NIEMEGEERS; K H SCHELLEKENS; F J VERBRUGGEN; J M VAN NUETEN
Journal:  Arzneimittelforschung       Date:  1963-03

2.  Blockade of central dopaminergic receptors of morphine: effect of haloperidol, apomorphine or benztropine.

Authors:  S K Puri; C Reddy; H Lal
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1973-03

3.  Clinical evaluation in 112 psychiatric patients of a butyrophenone neuroleptic, dehydrobenzperidol (R 4749). A controlled study in 45 patients of dehydrobenzperidol versus haloperidol.

Authors:  E Cocito; G Ambrosini; A Arata; P Bevilacqua; E Tortora
Journal:  Arzneimittelforschung       Date:  1970-08

Review 4.  Cardiac toxicity and psychotropic drugs.

Authors:  G E Crane
Journal:  Dis Nerv Syst       Date:  1970-08

5.  Increased synthesis of catecholamines in the intact rat following administration of alpha-adrenergic blocking agents.

Authors:  W Dairman; R Gordon; S Spector; A Sjoerdsma; S Udenfriend
Journal:  Mol Pharmacol       Date:  1968-09       Impact factor: 4.436

6.  Acceleration of turnover of 14C-catecholamines in rat brain by chlorpromazine.

Authors:  K F Gey; A Pletscher
Journal:  Experientia       Date:  1968-04-15

7.  Further studies on the accumulation and disappearance of catecholamines formed from tyrosine-14C in mouse brain. Effect of some phenothiazine analogues.

Authors:  H Nybäck; G Sedvall
Journal:  Eur J Pharmacol       Date:  1970-05       Impact factor: 4.432

8.  Application of steady state kinetics to the estimation of synthesis rate and turnover time of tissue catecholamines.

Authors:  B B Brodie; E Costa; A Dlabac; N H Neff; H H Smookler
Journal:  J Pharmacol Exp Ther       Date:  1966-12       Impact factor: 4.030

9.  The effects of acutely administered analgesics on the turnover of noradrenaline and dopamine in various regions of the rat brain.

Authors:  M F Sugrue
Journal:  Br J Pharmacol       Date:  1974-10       Impact factor: 8.739

Review 10.  Dopamine (3-hydroxytyramine) and brain function.

Authors:  O Hornykiewicz
Journal:  Pharmacol Rev       Date:  1966-06       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.